Long-term Follow-up of Participants Dosed with an Investigational Gene Editing Therapy for Cardiovascular Disease
Launched by VERVE THERAPEUTICS, INC. · Oct 31, 2023
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • 1. A participant has completed or discontinued from a Verve sponsored clinical study in which they received at least one dose of study drug.
- • 2. A participant has provided informed consent for LTF-001.
- • Exclusion Criteria: N/A
About Verve Therapeutics, Inc.
Verve Therapeutics, Inc. is a pioneering biotechnology company focused on transforming the treatment of cardiovascular disease through innovative gene editing and therapeutic approaches. By leveraging cutting-edge technologies, Verve aims to develop single-course therapies that provide lasting protection against heart disease, thereby addressing the root causes rather than just the symptoms. With a commitment to advancing precision medicine, the company is dedicated to improving patient outcomes and enhancing the quality of life for individuals at risk of cardiovascular conditions. Through rigorous clinical trials and research, Verve Therapeutics is at the forefront of redefining the future of cardiovascular care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Auckland, , New Zealand
Christchurch, , New Zealand
London, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported